Key result
Random Forest model predicts cardiac autonomic neuropathy with ~99% accuracy in diabetic patients.
Why the study?
Microvascular complications are a key cause of mortality in type 2 diabetes, prompting investigation into a machine learning approach to predict these complications using demographic, clinical, and laboratory profiles.
Does a machine learning approach using demographic, clinical, and laboratory profiles accurately predict microvascular complications in patients with type 2 diabetes?
Cross-Sectional (n=103)
No
Does a machine learning approach using demographic, clinical, and laboratory profiles accurately predict microvascular complications in patients with type 2 diabetes?
Machine learning models using routine demographic, clinical, and laboratory data can accurately predict microvascular complications in patients with type 2 diabetes, potentially reducing the need for specialized diagnostic testing.
May support ML screening for CAN in type 2 diabetes; hypothesis-generating and requires prospective validation before practice change.
Microvascular complications are one of the key causes of mortality among type 2 diabetic patients. This study was sought to investigate the use of a novel machine learning approach for predicting these complications using only the patient demographic, clinical, and laboratory profiles. A total of 96 Bangladeshi participants with type 2 diabetes were recruited during their routine hospital visits. All patient profiles were assessed by using a chi-squared (χ2) test to statistically determine the most important markers in predicting three microvascular complications: cardiac autonomic neuropathy (CAN), diabetic peripheral neuropathy (DPN), and diabetic retinopathy (RET). A machine learning approach based on logistic regression, random forest (RF), and support vector machine (SVM) algorithms was then developed to ensure automated clinical testing for microvascular complications in diabetic patients. The highest prediction accuracies were obtained by RF using diastolic blood pressure, albumin–creatinine ratio, and gender for CAN testing (98.67%); microalbuminuria, smoking history, and hemoglobin A1C for DPN testing (67.78%); and hemoglobin A1C, microalbuminuria, and smoking history for RET testing (84.38%). This study suggests machine learning as a promising automated tool for predicting microvascular complications in diabetic patients using their profiles, which could help prevent those patients from further microvascular complications leading to early death.
No takes yet. Share an insight, caveat, or question.
Rashid et al. (2022) conducted a cross-sectional in Type 2 diabetes mellitus (n=103). Machine learning models (Random Forest, SVM, Logistic Regression) using demographic, clinical, and laboratory profiles was evaluated on Prediction accuracy for microvascular complications (CAN, DPN, RET). A Random Forest machine learning model using demographic, clinical, and laboratory profiles achieved prediction accuracies of 98.67% for cardiac autonomic neuropathy, 67.78% for diabetic peripheral neuropathy, and 84.38% for diabetic retinopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: